BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...biologic targeting all three TAM family members; Incyte Corp.’s small molecule INCB81776 and Pharm Group’s CT413...
BioCentury | Jan 15, 2018
Preclinical News

Combination therapy could treat tumors resistant to MAPK pathway inhibitors

...entered preclinical development since then -- anti-Axl kinase mAb BGB149 from BerGenBio ASA (OSE:BGBIO) and CT413...
Items per page:
1 - 2 of 2